The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

It came out of nowhere for Elizabeth Williams. Life-changing news started with what seemed like a simple cough.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the ...

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...

The 10-week course at Stanford last fall was fully enrolled and packed with students eager to learn from Dr. Lin's unique ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...